Participant flow

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies · Source last updated 2013-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   0.015 mg/kg/dose of ALT-801

   id

   FG000

   title

   ALT-801 0.015 mg/kg/Dose

2. description

   0.040 mg/kg/dose of ALT-801

   id

   FG001

   title

   ALT-801 0.040 mg/kg/ Dose

3. description

   0.080 mg/kg/dose of ALT-801

   id

   FG002

   title

   ALT-801 0.080 mg/kg/Dose

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         16

      3. group Id

         FG002

         num Subjects

         6

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         15

      3. group Id

         FG002

         num Subjects

         6

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Between 08-2007 and 05-2009, 118 patients were consented and screened, 56 were Human leukocyte antigen (HLA)-A2 positive and had tumor specimens that were positive for target p53 (aa 264-272)/HLA-A\*0201 complex. Thirty HLA-A2-positive patients with p53/HLA-A\*0201 tumors either withdrew consent or did not meet other inclusion/exclusion criteria.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice